-
Pembrolizumab, sold
under the
brand name Keytruda, is a
humanized antibody, more
specifically a PD-1 inhibitor, used in
cancer immunotherapy that treats...
- Favezelimab/
pembrolizumab is a fixed-dose
combination of two
monoclonal antibodies developed by
Merck to
treat various cancers. Timmerman, John; Lavie...
-
drugs or products, each with over $1
billion in revenue:
Keytruda (
pembrolizumab), a
humanized antibody used in
cancer immunotherapy that had $14.3 billion...
-
checkpoint inhibitors include antibodies such as ipilimumab, nivolumab, and
pembrolizumab.
Dendritic cell
therapy provokes anti-tumor
responses by
causing dendritic...
- and
liver and that he had
begun treatment with the
immunotherapy drug
pembrolizumab and was
about to
start radiation therapy. His
healthcare was managed...
- As
adjuvant therapy, mRNA-4157
monotherapy and in
combination with
pembrolizumab have been
investigated in
patients with
resected solid tumors (melanoma...
- system.
Atezolizumab is an anti-PD-L1
monoclonal antibody.
Nivolumab and
Pembrolizumab are anti-PD-1
monoclonal antibodies.
Ipilimumab is a
monoclonal antibody...
-
chemoresistant MSI-high
tumors can be
treated with
dostarlimab and
pembrolizumab. In the
European Union,
dostarlimab is
indicated as
monotherapy for...
-
clinical and
observational studies,
immune checkpoint inhibitors (e.g.,
pembrolizumab) have been
tested in
mucosal melanomas and have
shown promising response...
- PD-L1, but are
sometimes effective in
those that do not.
Treatment with
pembrolizumab, atezolizumab, or
combination nivolumab plus
ipilimumab are all superior...
